Moderna Announces Agreement with Sanofi for Fill/Finish Manufacturing of COVID-19 Vaccine
Product News Apr 27, 2021
Credit: torstensimon/ Pixabay
Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, has announced that it has entered into an agreement with Sanofi (Nasdaq: SNY) for fill/finish sterile manufacturing services and supply packaging for up to 200 million doses of the Moderna COVID-19 Vaccine in the U.S. beginning in September 2021. Sanofi will leverage its established manufacturing infrastructure at its site in Ridgefield, NJ.
“We welcome the opportunity to work with Sanofi on fill/finish manufacturing for the Moderna COVID-19 Vaccine in the U.S. We would like to thank the Department of Health and Human Services and the Biden Administration for their assistance in securing this additional capacity,” said Juan Andres, Moderna’s Chief Technical Operations and Quality Officer. “This additional production will help us continue to scale up our manufacturing capacity in the United States.”